Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: SemiMaintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. | Zhao et al. Radiation Oncology 2010 5 12 http content 5 1 12 RADIATION ONCOLOGY STUDY PROTOCOL Open Access Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma a phase I II study 1 1 7 f I-X 1 1 2 3 2 -7 1 1 Jian-Dong Zhao Jin Liu Zhi-Gang Ren Ke Gu Zhen-Hua Zhou Wen-Tao Li Zhen Chen Zhi-Yong Xu Lu-Ming Liu2 Guo-Liang Jiang1 Abstract Background Three-dimensional conformal radiation therapy 3DCRT intensity-modulated radiation therapy IMRT combined with or without transcatheter arterial chemoembolization TACE for locally advanced hepatocellular carcinoma HCC has shown favorable outcomes in local control and survival of locally advanced HCC. However intra-hepatic spreading and metastasis are still the predominant treatment failure patterns. Sorafenib is a multikinase inhibitor with effects against tumor proliferation and angiogenesis. Maintenance Sorafenib would probably prevent or delay the intrahepatic and extrahepatic spread of HCC after radiotherapy which provides the rationale for the combination of these treatment modalities. Methods and design Patients with solitary lesion bigger than 5 cm in diameter histologically or cytologically confirmed HCC receive TACE 1-3 cycles plus 3DCRT IMRT 4-6 weeks later. Maintenance Sorafenib will be administered only for the patients with non-progression disease 4 to 6 weeks after the completion of radiotherapy. The dose will be 400 mg . twice a day. Sorafenib will be continuously given for 12 months unless intolerable toxicities and or tumor progression. If no more than 3 patients discontinue Sorafenib treatment who experience dose-limiting toxicity after necessary dose modification and delay and or radiation-induced liver disease in the first 15 enrolled patients the study will recruit second fifteen patients for .
